

Manuel Posada De La Paz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11946917/publications.pdf>

Version: 2024-02-01

32
papers

849
citations

623734

14
h-index

501196

28
g-index

35
all docs

35
docs citations

35
times ranked

760
citing authors

#	ARTICLE	IF	CITATIONS
1	Toxic oil syndrome: health-related quality-of-life assessment using the SF-36 Health Survey. <i>International Journal of Epidemiology</i> , 2022, 51, 491-500.	1.9	4
2	Determinants of satisfaction with the detection process of autism in Europe: Results from the ASDEU study. <i>Autism</i> , 2022, 26, 2136-2150.	4.1	3
3	Early Detection, Diagnosis and Intervention Services for Young Children with Autism Spectrum Disorder in the European Union (ASDEU): Family and Professional Perspectives. <i>Journal of Autism and Developmental Disorders</i> , 2020, 50, 3380-3394.	2.7	41
4	The RD-Connect Registry & Biobank Finder: a tool for sharing aggregated data and metadata among rare disease researchers. <i>European Journal of Human Genetics</i> , 2018, 26, 631-643.	2.8	33
5	Building a theoretical framework for autism spectrum disorders screening instruments in Europe. <i>Child and Adolescent Mental Health</i> , 2018, 23, 359-367.	3.5	3
6	Mortality Statistics and their Contribution to Improving the Knowledge of Rare Diseases Epidemiology: The Example of Hereditary Ataxia in Europe. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1031, 521-533.	1.6	6
7	Rare Disease Biospecimens and Patient Registries: Interoperability for Research Promotion, a European Example: EuroBioBank and SpainRDR-BioNER. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1031, 141-147.	1.6	3
8	Overview of existing initiatives to develop and improve access and data sharing in rare disease registries and biobanks worldwide. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 729-739.	0.8	6
9	The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases. <i>European Journal of Human Genetics</i> , 2015, 23, 1116-1123.	2.8	63
10	Screening for autism spectrum disorders: state of the art in Europe. <i>European Child and Adolescent Psychiatry</i> , 2014, 23, 1005-1021.	4.7	77
11	Respiratory Diseases Registries in the National Registry of Rare Diseases. <i>Archivos De Bronconeumologia</i> , 2014, 50, 397-403.	0.8	1
12	Registros de enfermedades respiratorias integrados en el Registro Nacional de Enfermedades Raras. <i>Archivos De Bronconeumologia</i> , 2014, 50, 397-403.	0.8	5
13	Proteomics of toxic oil syndrome in humans: Phenotype distribution in a population of patients. <i>Chemico-Biological Interactions</i> , 2011, 192, 129-135.	4.0	4
14	High prevalence of cardiovascular risk in patients with toxic oil syndrome: A comparative study using the general Spanish population. <i>European Journal of Internal Medicine</i> , 2008, 19, 32-39.	2.2	15
15	Quality of life, disability and handicap in patients with toxic oil syndrome. <i>Journal of Advanced Nursing</i> , 2005, 50, 595-604.	3.3	5
16	Neurologic Outcomes of Toxic Oil Syndrome Patients 18 Years after the Epidemic. <i>Environmental Health Perspectives</i> , 2003, 111, 1326-1334.	6.0	10
17	The Spanish toxic oil syndrome 20 years after its onset: a multidisciplinary review of scientific knowledge.. <i>Environmental Health Perspectives</i> , 2002, 110, 457-464.	6.0	56
18	On-Line HPLC-UV-mass spectrometry and tandem mass spectrometry for the rapid delineation and characterization of differences in complex mixtures: a case study using toxic oil variants. <i>Biomedical Chromatography</i> , 2002, 16, 311-318.	1.7	4

#	ARTICLE	IF	CITATIONS
19	The Spanish Toxic Oil Syndrome 20 Years after Its Onset: A Multidisciplinary Review of Scientific Knowledge. <i>Environmental Health Perspectives</i> , 2002, 110, 457-464.	6.0	86
20	Pathology of "Toxic Oils" and Selected Metals in the MRL/lpr Mouse. <i>Toxicologic Pathology</i> , 2001, 29, 630-638.	1.8	5
21	Epidemiologic Evidence for a New Class of Compounds Associated with Toxic Oil Syndrome. <i>Epidemiology</i> , 1999, 10, 130-134.	2.7	61
22	Late Deaths among Young Women Affected by the Toxic Oil Syndrome in Spain. <i>Epidemiology</i> , 1999, 10, 345.	2.7	6
23	Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome. , 1998, 12, 255-261.		10
24	Health Status Measurement in Toxic Oil Syndrome. <i>Journal of Clinical Epidemiology</i> , 1998, 51, 867-873.	5.0	22
25	Analytical Measurements of Products of Aniline and Triglycerides in Oil Samples Associated with the Toxic Oil Syndrome. <i>Archives of Toxicology Supplement</i> , 1997, 19, 53-64.	0.7	4
26	Epidemiology of the Toxic Oil Syndrome. <i>Archives of Toxicology Supplement</i> , 1997, 19, 41-52.	0.7	9
27	Products of Aniline and Triglycerides in Oil Samples Associated with the Toxic Oil Syndrome. <i>Chemical Research in Toxicology</i> , 1996, 9, 1001-1006.	3.3	21
28	Factors Associated with Pathogenicity of Oils Related to the Toxic Oil Syndrome Epidemic in Spain. <i>Epidemiology</i> , 1994, 5, 404-409.	2.7	26
29	Mortality among People Affected by Toxic Oil Syndrome. <i>International Journal of Epidemiology</i> , 1993, 22, 1077-1084.	1.9	14
30	Toxic oil syndrome: A current clinical and epidemiologic summary, including comparisons with the eosinophilia-myalgia syndrome. <i>Journal of the American College of Cardiology</i> , 1991, 18, 711-717.	2.8	63
31	CHEMICAL CORRELATES OF PATHOGENICITY OF OILS RELATED TO THE TOXIC OIL SYNDROME EPIDEMIC IN SPAIN. <i>American Journal of Epidemiology</i> , 1988, 127, 1210-1227.	3.4	121
32	Compositional Analysis of Oil Samples Implicated in the Spanish Toxic Oil Syndrome. <i>Journal of Food Science</i> , 1987, 52, 1562-1569.	3.1	32